Interpace Biosciences, Inc.
IDXG
$1.14
-$0.03-2.56%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 46.93M | 44.72M | 41.50M | 40.48M | 40.04M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 46.93M | 44.72M | 41.50M | 40.48M | 40.04M |
| Cost of Revenue | 17.00M | 16.42M | 15.75M | 15.33M | 14.98M |
| Gross Profit | 29.93M | 28.30M | 25.74M | 25.15M | 25.06M |
| SG&A Expenses | 21.14M | 20.13M | 19.35M | 19.82M | 19.59M |
| Depreciation & Amortization | -- | 27.00K | 226.00K | 544.00K | 862.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.82M | 37.21M | 35.91M | 36.32M | 36.07M |
| Operating Income | 8.11M | 7.51M | 5.59M | 4.16M | 3.96M |
| Income Before Tax | 6.95M | 6.05M | 4.16M | 2.42M | 2.28M |
| Income Tax Expenses | 4.00K | 17.00K | 17.00K | 17.00K | 17.00K |
| Earnings from Continuing Operations | 6.95 | 6.04 | 4.15 | 2.41 | 2.26 |
| Earnings from Discontinued Operations | -244.00K | -185.00K | -189.00K | -335.00K | -310.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.70M | 5.85M | 3.96M | 2.07M | 1.95M |
| EBIT | 8.11M | 7.51M | 5.59M | 4.16M | 3.96M |
| EBITDA | 8.41M | 7.79M | 6.02M | 4.88M | 4.99M |
| EPS Basic | 1.42 | 1.34 | 0.91 | 0.48 | 0.45 |
| Normalized Basic EPS | 0.99 | 0.87 | 0.60 | 0.35 | 0.33 |
| EPS Diluted | 0.92 | 1.34 | 0.91 | 0.47 | 0.45 |
| Normalized Diluted EPS | 0.62 | 0.86 | 0.60 | 0.35 | 0.33 |
| Average Basic Shares Outstanding | 17.55M | 17.47M | 17.40M | 17.33M | 17.27M |
| Average Diluted Shares Outstanding | 62.93M | 17.55M | 17.44M | 17.36M | 17.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |